Function-Preserving Surgery in Oral Cancer
09-12, 07:30–08:00 (Europe/Istanbul), Head & Neck Surgery 1

Oral cancer is one of the most prevalent cancers worldwide. Beyond survival rates, preserving function and maintaining quality of life are becoming increasingly important. This presentation aims to inform the audience about function-preservation strategies for patients with oral cancer.

Outcome Objectives:

  1. Understand the timing and purpose of neoadjuvant chemotherapy in oral cancer.

  2. Recognize the adverse effects of neoadjuvant chemotherapy and the predictors of these effects.

  3. Comprehend the resection philosophy, including post-chemotherapy volume versus initial tumor margin, and the strategy for adjuvant chemoradiotherapy.

  4. Learn about the application of sentinel node biopsy in patients with oral cancer.

  5. Understand the integration of neoadjuvant chemotherapy, safe-margin tumor resection, and sentinel node biopsy in oral cancer management.

Structure of the session:

Clinical scenario, Literature review, Interactive questions, and Take home message

Background:

  • Corresponding author

1.             Chiou LJ, Lee CC*. Modified Textbook Outcome was a Predictor for Early Mortality After Oral Cancer Surgery. Ann Surg Oncol. 2025;32:1301-1308. doi: 10.1245/s10434-024-16524-x

2.             Chang YM, Lee CC*. Stromal categorization of recurrent oral cancer after salvage surgery is associated with survival rates. Eur J Surg Oncol. 2024;50:108009. doi: 10.1016/j.ejso.2024.108009

3.             Chang YM, Lee CC*. Incorporation of stromal tumor-infiltrating lymphocytes into an early death prediction model significantly improves net reclassification for outcome estimation in advanced buccal cancer. J Craniomaxillofac Surg. 2024;52:843-849. doi: 10.1016/j.jcms.2024.04.007

4.             Hung CJ, Kang BH, Chang KM, Kang YY, Yin CH, Lee CC*. Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy. BMC Cancer. 2022;22:1084. doi: 10.1186/s12885-022-10152-y

5.             Lin SC, Lin YS, Kang BH, Yin CH, Chang KP, Chi CC, Lin MY, Su HH, Chang TS, She YY, ..Lee CC*. Sarcopenia results in poor survival rates in oral cavity cancer patients. Clin Otolaryngol. 2020;45:327-333. doi: 10.1111/coa.13481

6.             Yin CH, Kang BH, Liu WS, Pan LF, Chen HM, Lee CC*. New prediction tool-LIST-with improved prediction accuracy for 30-day readmission rates in patients with head and neck cancer after major cancer surgery. Oral Oncol. 2020;108:104772. doi: 10.1016/j.oraloncology.2020.104772

 

    1. Application of neoadjuvant chemotherapy in patients with both early and advanced oral cancer

    2. Performing function-preserving resection in patients with oral cancer after neoadjuvant chemotherapy

    3. Application of sentinel node biopsy in early-stage oral cancer

    4. Enabling the audience to integrate neoadjuvant chemotherapy, margin-free tumor resection, and sentinel node biopsy in oral cancer management
Ching-Chih Lee

Ching-Chih Lee is an associate professor and Chief of Rhinology-Head and neck surgery at Kaohsiung Veterans General Hospital, Taiwan. His work focuses specifically on the biomarkers of head and neck cancer, quality metrics in head and neck cancer, and skull base surgery. His recent publication can be found in Head Neck, EJSO, Oral Diseases, Journal of Otolaryngology-Head an Neck Surgery and Oral Oncolog.

This speaker also appears in: